Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1I2 | O75469 | 2/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 1.00 |
| ▸ | TBXA2R | P21731 | 2/20 | 1.00 |
| ▸ | AGTR1 | P30556 | 2/20 | 1.00 |
| ▸ | PTGIR | P43119 | 2/20 | 1.00 |
| ▸ | PDE4D | Q08499 | 2/20 | 1.00 |
| ▸ | PTGDR | Q13258 | 2/20 | 1.00 |
| ▸ | DRD1 | P21728 | 1/20 | 1.00 |
| ▸ | CKS1B | P61024 | 6/20 | 0.77 |
| ▸ | SKP1 | P63208 | 6/20 | 0.77 |
| ▸ | SKP2 | Q13309 | 6/20 | 0.77 |
| ▸ | CNR1 | P21554 | 3/20 | 0.77 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.77 |
| ▸ | HTR1A | P08908 | 1/20 | 0.77 |
| ▸ | HTR2A | P28223 | 1/20 | 0.77 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.77 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.77 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.77 |
| ▸ | HTR2B | P41595 | 1/20 | 0.77 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.77 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Laselipag SCHEMBL29355314 | 1.00 | NR1I2 (1.00) | NR1I2ADORA3TBXA2RAGTR1PTGIR | |
| Laselipag SCHEMBL26906440 | 1.00 | NR1I2 (1.00) | NR1I2ADORA3TBXA2RAGTR1PTGIR | |
| Laselipag SCHEMBL30605680 | 0.99 | NR1I2 (0.98) | NR1I2ADORA3TBXA2RAGTR1PTGIR | |
| SCHEMBL19820818 | 0.99 | NR1I2 (0.98) | NR1I2ADORA3TBXA2RAGTR1PTGIR | |
| SCHEMBL19823563 | 0.95 | NR1I2 (0.90) | NR1I2ADORA3TBXA2RAGTR1PTGIR | |
| SCHEMBL19823490 | 0.93 | NR1I2 (0.86) | NR1I2ADORA3TBXA2RAGTR1PTGIR | |
| SCHEMBL19823469 | 0.92 | NR1I2 (0.85) | NR1I2ADORA3TBXA2RAGTR1PTGIR | |
| SCHEMBL5214914 | 0.92 | PTGIR (0.84) | NR1I2ADORA3TBXA2RAGTR1PTGIR | |
| SCHEMBL5214095 | 0.92 | NR1I2 (0.84) | NR1I2ADORA3TBXA2RAGTR1PTGIR | |
| Laselipag SCHEMBL28689935 | 0.91 | NR1I2 (0.83) | NR1I2ADORA3TBXA2RAGTR1PTGIR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 291 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250034098-A1 | CRYSTALLINE SUBSTITUTED PYRAZINES AS PGI2 RECEPTOR AGONISTS | NIPPON SHINYAKU CO., LTD. (JP) | 2025-01-30 | — | — | US | claimed |
| US-20240425463-A1 | PROCESS FOR MANUFACTURING A DIPHENYLPHRAZINE DERIVATIVE | ACTELION PHARMACEUTICALS LTD (CH) | 2024-12-26 | — | — | US | claimed |
| US-12152009-B2 | Crystalline substituted pyrazines as PGI2 receptor agonists | NIPPON SHINYAKU CO., LTD. (JP) | 2024-11-26 | — | — | US | claimed |
| US-20240216366-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A DIPHENYLPYRAZINE DERIVATIVE | ACTELION PHARMACEUTICALS LTD (CH) | 2024-07-04 | — | — | US | claimed |
| US-20240197724-A1 | THERAPEUTIC AGENT FOR GAIT DISTURBANCE | NIPPON SHINYAKU CO., LTD. (JP) | 2024-06-20 | — | — | US | claimed |
| EP-4371617-A2 | CRYSTAL | Nippon Shinyaku Co., Ltd. (JP) | 2024-05-22 | — | — | EP | claimed |
| US-20240091223-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A DIPHENYLPYRAZINE DERIVATIVE | ACTELION PHARMACEUTICALS LTD (CH) | 2024-03-21 | — | — | US | claimed |
| US-20240082154-A1 | DISEASE-SITE-SPECIFIC LIPOSOMAL FORMULATION | CUORIPS INC. (JP) | 2024-03-14 | — | — | US | claimed |
| EP-4316489-A1 | THERAPEUTIC AGENT FOR GAIT DISTURBANCE | Nippon Shinyaku Co., Ltd. (JP) | 2024-02-07 | — | — | EP | claimed |
| CN-117510418-A | Crystallization | 日本新药株式会社 | 2024-02-06 | — | — | CN | claimed |
| EP-2315587-A2 | THERAPEUTIC COMPOSITIONS CONTAINING MACITENTAN | Actelion Pharmaceuticals Ltd. (CH) | 2011-05-04 | — | — | EP | claimed |
| EP-2292231-A1 | THERAPEUTIC AGENT FOR SPINAL CANAL STENOSIS | Nippon Shinyaku Co., Ltd. (JP) | 2011-03-09 | — | — | EP | claimed |
| US-20110015211-A1 | FIBROSIS INHIBITOR | NIPPON SHINYAKU CO., LTD. (JP) | 2011-01-20 | — | — | US | claimed |
| EP-2246336-A1 | FIBROSIS INHIBITOR | Nippon Shinyaku Co., Ltd. (JP) | 2010-11-03 | — | — | EP | claimed |
| WO-2010075861-A2 | METHODS OF IDENTIFYING CRITICALLY ILL PATIENTS AT INCREASED RISK OF DEVELOPMENT OF ORGAN FAILURE AND COMPOUNDS FOR THE TREATMENT HEREOF | THROMBOLOGIC APS (DK) | 2010-07-08 | — | — | WO | claimed |
| WO-2010018549-A2 | THERAPEUTIC COMPOSITIONS CONTAINING MACITENTAN | ACTELION PHARMACEUTICALS LTD (CH) | 2010-02-18 | — | — | WO | claimed |
| US-7205302-B2 | Anticoagulants; antilipemic agents; cardiovascular disorders | NIPPON SHINYAKU CO., LTD. (JP) | 2007-04-17 | — | — | US | claimed |
| EP-1400518-B1 | HETEROCYCLIC COMPOUND DERIVATIVES AND MEDICINES | NIPPON SHINYAKU CO LTD (JP) | 2007-01-17 | — | — | EP | claimed |
| US-20040102436-A1 | Heterocyclic compound derivatives and medicines | NIPPON SHINYAKU CO., LTD. (JP) | 2004-05-27 | — | — | US | claimed |
| EP-1400518-A1 | HETEROCYCLIC COMPOUND DERIVATIVES AND MEDICINES | Nippon Shinyaku Co., Ltd. (JP) | 2004-03-24 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250034098-A1 | CRYSTALLINE SUBSTITUTED PYRAZINES AS PGI2 RECEPTOR AGONISTS | GRK2, FFAR2, TBXA2R | NR1I2 28/4885ADORA3 132/4885TBXA2R 3/4885 |
| US-20110015211-A1 | FIBROSIS INHIBITOR | MMP1, ARG1, MMP8 | NR1I2 39/4885ADORA3 3400/4885TBXA2R 3040/4885 |
| US-12152009-B2 | Crystalline substituted pyrazines as PGI2 receptor agonists | GRK2, FFAR2, TBXA2R | NR1I2 27/4885ADORA3 133/4885TBXA2R 3/4885 |
| US-20240197724-A1 | THERAPEUTIC AGENT FOR GAIT DISTURBANCE | MT-ND6, NLN, CLN6 | NR1I2 1515/4885ADORA3 1650/4885TBXA2R 2871/4885 |
| US-20240091223-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A DIPHENYLPYRAZINE DERIVATIVE | IL5, CACNA1C, IAPP | NR1I2 2491/4885ADORA3 698/4885TBXA2R 116/4885 |
| US-20240425463-A1 | PROCESS FOR MANUFACTURING A DIPHENYLPHRAZINE DERIVATIVE | CACNA1H, CA2, CACNA1G | NR1I2 4219/4885ADORA3 1209/4885TBXA2R 91/4885 |
| US-20240082154-A1 | DISEASE-SITE-SPECIFIC LIPOSOMAL FORMULATION | LPAR2, PLA2R1, PTGDR2 | NR1I2 841/4885ADORA3 507/4885TBXA2R 11/4885 |
| US-20240216366-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A DIPHENYLPYRAZINE DERIVATIVE | IL5, CACNA1C, IAPP | NR1I2 2491/4885ADORA3 698/4885TBXA2R 116/4885 |
| US-20040102436-A1 | Heterocyclic compound derivatives and medicines | CNR2, CNR1, GPR55 | NR1I2 8/4885ADORA3 279/4885TBXA2R 20/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.